Zimbabwe Launches Lenacapavir HIV Drug

ZIMBABWE ROLLS OUT LONG-ACTING HIV PREVENTION DRUG LENACAPAVIR

Why in the News?

  • Public Health Initiative: Zimbabwe has launched rollout of long-acting injectable HIV prevention drug lenacapavir.
  • Global First Mover: It is among the first countries offering a twice-yearly injectable HIV preventive treatment.

Zimbabwe Launches Lenacapavir HIV Drug

LENACAPAVIR AND HIV PREVENTION STRATEGY

  • Long-Acting Protection: Lenacapavir provides six months’ HIV prevention through a biannual injectable regimen, improving adherence compared to daily pills.
  • Target Population: Initial phase targets 46,500 high-risk individuals, including young women and pregnant or breastfeeding mothers.
  • Free Provision: Drug is offered free to vulnerable groups, ensuring equitable access to preventive healthcare services.
  • Pharmaceutical Development: The medicine is developed by Gilead Sciences, highlighting role of private sector innovation in global health.
  • Global Partnerships: Rollout supported through PEPFAR and the Global Fund, demonstrating multilateral cooperation in disease control.

PUBLIC HEALTH AND POLICY IMPLICATIONS

  • Infection Control: Long-acting prophylaxis could significantly reduce new HIV infections, particularly in high-burden African nations.
  • Adherence Advantage: Reduced dosing frequency addresses challenges of treatment compliance and stigma-related discontinuation.
  • Maternal Health Linkage: Inclusion of pregnant and breastfeeding women strengthens mother-to-child transmission prevention efforts.
  • Health Financing Model: International donor support reflects continued reliance on global health financing mechanisms.
  • Equity Focus: Targeted prevention strategy aligns with principles of universal health coverage and vulnerable population protection.

HIV/AIDS PREVENTION AND GLOBAL HEALTH GOVERNANCE

●  HIV Burden: Sub-Saharan Africa remains disproportionately affected by HIV/AIDS, requiring sustained prevention strategies.

●  Preventive Tools: Pre-exposure prophylaxis (PrEP) and long-acting injectables complement antiretroviral therapy frameworks.

●  Global Institutions: Initiatives like PEPFAR and the Global Fund play central roles in combating infectious diseases.

●  Public Health Strategy: Effective HIV control integrates prevention, testing, treatment, and community outreach mechanisms.

●  UPSC Relevance: Topic relates to GS Paper II and III, covering health policy, international cooperation, and disease management strategies